Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
- 20 April 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (12), 1343-1349
- https://doi.org/10.1200/jco.2011.36.1824
Abstract
Interstitial deletions of chromosome 5q are common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), pointing toward the pathogenic role of this region in disease phenotype and clonal evolution. The higher level of resolution of single-nucleotide polymorphism array (SNP-A) karyotyping may be used to find cryptic abnormalities and to precisely define the topographic features of the genomic lesions, allowing for more accurate clinical correlations. We analyzed high-density SNP-A karyotyping at diagnosis for a cohort of 1,155 clinically well-annotated patients with malignant myeloid disorders. We identified chromosome 5q deletions in 142 (12%) of 1,155 patients and uniparental disomy segments (UPD) in four (0.35%) of 1,155 patients. Patients with deletions involving the centromeric and telomeric extremes of 5q have a more aggressive disease phenotype and additional chromosomal lesions. Lesions not involving the centromeric or telomeric extremes of 5q are not exclusive to 5q− syndrome but can be associated with other less aggressive forms of MDS. In addition, larger 5q deletions are associated with either del(17p) or UPD17p. In 31 of 33 patients with del(5q) AML, either a deletion involving the centromeric and/or telomeric regions or heterozygous mutations in NPM1 or MAML1 located in 5q35 were present. Our results suggest that the extent of the affected region on 5q determines clinical characteristics that can be further modified by heterozygous mutations present in the telomeric extreme.Keywords
This publication has 32 references indexed in Scilit:
- A novel tumour-suppressor function for the Notch pathway in myeloid leukaemiaNature, 2011
- Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5qLeukemia, 2010
- NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in LeukemiaPLOS ONE, 2010
- WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutationsLeukemia, 2010
- Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysisGenes, Chromosomes and Cancer, 2010
- Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid MalignanciesCancer Research, 2009
- TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17pLeukemia, 2009
- Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouseBlood, 2008
- Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AMLBlood, 2008
- Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5qJournal of Clinical Oncology, 2006